Colorectal Cancer
In recent years, researchers have considered a potential link between beta-blockers and a decreased risk of cancer. This theory stems from the fact that beta-blockers inhibit the actions of the stress hormone norepinephrine. This, along with studies that found norepinephrine can promote the growth and spread of cancer cells, led researchers to reason that the beta-blockers could have anticancer properties.
However, a recent study published early online in Cancer revealed that the use of beta-blockers showed no reduction of colorectal cancer risk.
Read More ›Updated analysis of disease-free survival (DFS) in the NO16968 trial confirms a survival benefit with the addition of oxaliplatin in adjuvant treatment of stage III colorectal cancer. The study compared XELOX (capecitabine plus oxaliplatin) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) in 1886 patients with resected stage III colon cancer, and the updated analysis was based on a median follow-up of 7 years. Read More ›
SAN FRANCISCO—For patients with colorectal cancer (CRC), advances in molecular profiling have led to an ex - plosion in novel agents specific for targets above and beyond the epidermal growth factor receptor (EGFR). Joseph Tabernero, MD, director of clinical research at Vall d’Hebron Institute of Oncology in Barcelona, Spain, previewed the future of treatment for CRC at the 2011 Gastrointestinal Cancers Symposium.
Read More ›Pharmacogenomics is the study of the role of inherited and acquired genetic variation in drug response.1 A focus of research in recent years on genome-wide association studies ultimately may help identify patient- and/or cancer-specific biomarkers that will facilitate optimization of drug therapy including guiding drug selection, dose, and treatment duration.2 The identification of the role of KRASmutations in select patients with colorectal cancer (CRC) who are candidates for epidermal growth factor receptor (EGFR) in hibitors is one example of the clinical a Read More ›
SALT LAKE CITY—Reliable tests are sorely needed to help determine the best dose regimen before chemotherapy to minimize toxicities for patients with metastatic colon cancer, according to a talk given at the annual meeting of the Hematology/Oncology Pharmacy Association.
Read More ›
Page 2 of 2
- 1
- 2